Form D · Biotechnology

IGC BIO INC.

Boston, MA · CIK 0001668051

Offering snapshot reported Jul 24, 2018 · SEC filing

Reported sold: $2.2M
Investors reported: 1
Minimum accepted: $0
First sale: Oct 27, 2017

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$1,500,000 → $2,200,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 24, 2018	Amendment	$1,650,000	$150,000vs Nov 13, 2017	1	SEC filing
Jul 24, 2018	Amendment	$2,200,000	$700,000vs Nov 13, 2017	1	SEC filing
Nov 13, 2017	Initial	$1,500,000	No comparison	1	SEC filing
Oct 14, 2016	Initial	$2,500,000	No comparison	1	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-298608

The total offering amount from the initial financing was increased by $550,000 from the same investor.

Source: Form D, filed Jul 24, 2018. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Tamar Erdfarb	Director
Joseph Jacobson	Director
Oded Kadosh	Director
Jeremy Wertheimer	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

50 Congress Street Suite 1040
Boston, MA, 02109